Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer.
暂无分享,去创建一个
Xiao-hua Hu | Yuhong Fan | Yuanzhi Wang | Change Hu | Ru-Xiang Li | Q. Pan
[1] N. Zengi̇n,et al. Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[2] A. Tentes,et al. Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[3] S. Chalikonda,et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. , 2015, Annals of surgery.
[4] Rongguo Li,et al. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway , 2015, OncoTargets and therapy.
[5] Hu Chen,et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer , 2014, BMC Cancer.
[6] Y. Zeng,et al. Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.
[7] Robert C. G. Martin,et al. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. , 2014, Journal of the American College of Surgeons.
[8] H. Harizi. Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology , 2013, Cellular and Molecular Immunology.
[9] A. Mikelsaar,et al. Epitope of titin A-band-specific monoclonal antibody Tit1 5 H1.1 is highly conserved in several Fn3 domains of the titin molecule. Centriole staining in human, mouse and zebrafish cells , 2012, Cell Division.
[10] Kecheng Xu,et al. Cryosurgery for lung cancer. , 2012, Journal of thoracic disease.
[11] E. Leen,et al. Irreversible Electroporation for Focal Ablation at the Porta Hepatis , 2012, CardioVascular and Interventional Radiology.
[12] Li-Zhi Liu,et al. Autologous Cytokine-induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma , 2012, Journal of immunotherapy.
[13] Helen Kavnoudias,et al. Investigation of the safety of irreversible electroporation in humans. , 2011, Journal of vascular and interventional radiology : JVIR.
[14] Jens Ricke,et al. Irreversible Electroporation of Renal Cell Carcinoma: A First-in-Man Phase I Clinical Study , 2011, CardioVascular and Interventional Radiology.
[15] D. Dupuy,et al. Irreversible electroporation of the pancreas in swine: a pilot study. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[16] Kenneth J. Chang,et al. Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.
[17] Boris Rubinsky,et al. Tumor Ablation with Irreversible Electroporation , 2007, PloS one.
[18] Boris Rubinsky,et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation , 2006, IEEE Transactions on Biomedical Engineering.
[19] Boris Rubinsky,et al. Electrical impedance tomography for imaging tissue electroporation , 2004, IEEE Transactions on Biomedical Engineering.
[20] S. Bagla,et al. Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report. , 2012, Journal of vascular and interventional radiology : JVIR.
[21] L. Downs,et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.
[22] B. Rubinsky,et al. Tissue Ablation with Irreversible Electroporation , 2005, Annals of Biomedical Engineering.
[23] N. Dubrawsky. Cancer statistics , 2022 .